Products from BPS Bioscience require a minimum order value above 400€Applications: Generate a stable cell line expressing human BCMA with G418 selection and limiting dilution
Background: B-cell maturation antigen (BCMA, also known as CD269 or tumor necrosis factor receptor superfamily member 17, TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in non-malignant tissue but almost universal expression on MM cells. CAR T cells targeting BCMA have clinical anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy breakthrough designation in Multiple Myeloma.
Description: The BCMA Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. The particles contain a human BCMA (NM_ 001192) driven by a CMV promoter and a G418 selection marker (Figure 1).
Figure 1: Schematic of the lenti-vector used to generate the BCMA Lentivirus
Formulation: The lentivirus particles were produced from HEK293T cells. They are supplied in cell culture medium containing 90% DMEM + 10% FBS.
Storage Stability: Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C.
Supplied As: Two vials (500 µl x 2) of lentivirus at a titer ≥10
7 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
Uniprot: Q02223
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-2
English
Deutsch
